EGFR and neoplasm: Li designed CuS-Ab NPs loaded with cetuximab to target EGFR to inhibit angiogenesis and tumor growth and to promote the accumulation of CuS NPs in tumors; these NPs reduce the laser energy required for PTT therapy and reduce damage to normal tissue [110].